Annji Pharmaceutical Co., Ltd.(TW:7754)
NT$69.40+8.20 (+13.40%)
TW:7754
Annji Pharmaceutical Co., Ltd. financials statements
NT$69.40
At close:+8.20 (+13.40%)
Annji Pharmaceutical Co., Ltd. (7754) Ratios
Annji Pharmaceutical Co., Ltd. Ratios
TW:7754's free cash flow for Q2 2026 was NT$-181.58M. For the 2026 fiscal year, TW:7754's free cash flow was decreased by NT$-407.00K and operating cash flow was NT$-181.18M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.60 | 2.56 | 4.04 | 9.94 | 25.37 |
| Quick Ratio | 3.42 | 2.47 | 4.04 | 9.79 | 25.04 |
| Cash Ratio | 3.37 | 2.17 | 2.63 | 8.72 | 24.09 |
| Solvency Ratio | -1.16 | -0.91 | -1.03 | -6.39 | -9.57 |
| Operating Cash Flow Ratio | -3.41 | -0.64 | -0.30 | -6.17 | -8.64 |
| Short-Term Operating Cash Flow Coverage | -55.97 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 99.49M | NT$ 403.90M | NT$ 635.88M | NT$ 274.79M | NT$ 395.77M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.06 | 0.05 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.15 | 0.08 | 0.07 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.13 | 0.08 | 0.06 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.85 | 1.51 | 1.31 | 1.06 | 1.03 |
| Debt Service Coverage Ratio | -41.25 | -176.87 | -616.67 | -6131.03 | -1045.67 |
| Interest Coverage Ratio | -230.71 | -202.10 | -570.32 | -7515.47 | -1348.50 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.54 | 0.61 | 0.80 | 0.00 | 0.07 |
| Net Debt to EBITDA | 0.92 | 1.82 | 2.13 | 1.38 | 2.48 |
| Profitability Margins | |||||
| Gross Profit Margin | -581.36% | 9.22% | 12.85% | 68.57% | 68.01% |
| EBIT Margin | -4891.01% | -373.40% | -202.26% | -14454.24% | -13831.85% |
| EBITDA Margin | -4293.01% | -326.80% | -175.58% | -11968.08% | -10931.22% |
| Operating Profit Margin | -4891.01% | -373.40% | -187.15% | -14790.59% | -14095.82% |
| Pretax Profit Margin | -4738.73% | -367.02% | -202.59% | -14456.21% | -13842.30% |
| Net Profit Margin | -4738.73% | -367.02% | -229.37% | -14554.12% | -13841.46% |
| Continuous Operations Profit Margin | -4738.73% | -367.02% | -229.37% | -14554.12% | -13841.46% |
| Net Income Per EBT | 100.00% | 100.00% | 113.22% | 100.68% | 99.99% |
| EBT Per EBIT | 96.89% | 98.29% | 108.25% | 97.74% | 98.20% |
| Return on Assets (ROA) | -60.64% | -35.33% | -27.25% | -43.72% | -29.80% |
| Return on Equity (ROE) | -111.90% | -53.46% | -35.59% | -46.36% | -30.55% |
| Return on Capital Employed (ROCE) | -75.79% | -50.62% | -27.40% | -47.11% | -31.11% |
| Return on Invested Capital (ROIC) | -74.83% | -50.20% | -27.24% | -47.11% | -30.97% |
| Return on Tangible Assets | -68.40% | -39.27% | -30.67% | -63.53% | -42.83% |
| Earnings Yield | -7.39% | -10.95% | -8.81% | -7.47% | -9.10% |
| Efficiency Ratios | |||||
| Receivables Turnover | 13.41 | 118.20 | 72.42 | 0.13 | 0.14 |
| Payables Turnover | 0.00 | 761.36 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 2.84 | 3.19 | 0.00 | 0.10 | 0.09 |
| Fixed Asset Turnover | 0.11 | 1.26 | 1.75 | 0.24 | 0.13 |
| Asset Turnover | 0.01 | 0.10 | 0.12 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.02 | 0.17 | 0.30 | 0.00 | 0.00 |
| Cash Conversion Cycle | 155.67 | 116.90 | 5.04 | 6315.35 | 6896.91 |
| Days of Sales Outstanding | 27.21 | 3.09 | 5.04 | 2823.92 | 2672.77 |
| Days of Inventory Outstanding | 128.46 | 114.29 | 0.00 | 3491.43 | 4224.14 |
| Days of Payables Outstanding | 0.00 | 0.48 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 155.67 | 117.38 | 5.04 | 6315.35 | 6896.91 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.70 | -2.00 | -0.87 | -2.89 | -3.11 |
| Free Cash Flow Per Share | -3.74 | -2.12 | -1.03 | -2.92 | -3.19 |
| Dividend Paid and CapEx Coverage Ratio | -93.78 | -17.69 | -5.43 | -94.41 | -37.49 |
| Capital Expenditure Coverage Ratio | -93.78 | -17.69 | -5.43 | -94.41 | -37.49 |
| Operating Cash Flow Coverage Ratio | -7.10 | -3.36 | -1.10 | 0.00 | -50.32 |
| Operating Cash Flow to Sales Ratio | -46.38 | -1.93 | -0.47 | -116.54 | -97.83 |
| Free Cash Flow Yield | -7.31% | -6.08% | -2.13% | -6.05% | -6.60% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -13.54 | -9.13 | -11.36 | -13.38 | -11.00 |
| Price-to-Sales (P/S) Ratio | 641.51 | 33.52 | 26.05 | 1947.27 | 1521.33 |
| Price-to-Book (P/B) Ratio | 15.15 | 4.88 | 4.04 | 6.20 | 3.36 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -13.68 | -16.45 | -46.98 | -16.53 | -15.15 |
| Price-to-Operating Cash Flow Ratio | -13.83 | -17.38 | -55.63 | -16.71 | -15.55 |
| Price-to-Earnings Growth (PEG) Ratio | 17.20 | 0.88 | -0.64 | 0.75 | 0.00 |
| Enterprise Value Multiple | -14.03 | -8.44 | -12.70 | -14.89 | -11.44 |
| Enterprise Value | 4.55B | 2.66B | 3.20B | 2.90B | 1.79B |
| EV to EBITDA | -14.03 | -8.44 | -12.70 | -14.89 | -11.44 |
| EV to Sales | 602.17 | 27.57 | 22.31 | 1782.51 | 1250.52 |
| EV to Free Cash Flow | -12.85 | -13.53 | -40.23 | -15.14 | -12.45 |
| EV to Operating Cash Flow | -12.98 | -14.29 | -47.65 | -15.30 | -12.78 |
| Tangible Book Value Per Share | 2.67 | 6.04 | 10.21 | 5.21 | 9.90 |
| Shareholders’ Equity Per Share | 3.38 | 7.13 | 11.95 | 7.79 | 14.38 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.13 | -0.01 | 0.00 |
| Revenue Per Share | 0.08 | 1.04 | 1.85 | 0.02 | 0.03 |
| Net Income Per Share | -3.78 | -3.81 | -4.25 | -3.61 | -4.39 |
| Tax Burden | 1.00 | 1.00 | 1.13 | 1.01 | 1.00 |
| Interest Burden | 0.97 | 0.98 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 40.48 | 3.33 | 1.72 | 137.41 | 128.52 |
| SG&A to Revenue | 2.61 | 0.49 | 0.28 | 11.18 | 13.12 |
| Stock-Based Compensation to Revenue | 1.07 | 0.49 | 0.34 | 4.09 | 2.11 |
| Income Quality | 0.98 | 0.53 | 0.23 | 0.81 | 0.71 |
Currency in TWD
